argenx SE

ENXTBR:ARGX Voorraadrapport

Marktkapitalisatie: €42.9b

argenx Toekomstige groei

Future criteriumcontroles 5/6

argenx zal naar verwachting groeien in winst en omzet met respectievelijk 21.6% en 16.9% per jaar. De winst per aandeel zal naar verwachting groeien met 21.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 20.4% zijn.

Belangrijke informatie

21.6%

Groei van de winst

21.11%

Groei van de winst per aandeel

Biotechs winstgroei21.1%
Inkomstengroei16.9%
Toekomstig rendement op eigen vermogen20.44%
Dekking van analisten

Good

Laatst bijgewerkt18 May 2026

Recente toekomstige groei-updates

Recent updates

Nieuw narratief • May 20

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.
Narratiefupdate • May 14

ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power

Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.
Narratiefupdate • Apr 29

ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential

Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.
Narratiefupdate • Apr 15

ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power

Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.
Narratiefupdate • Apr 01

ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential

Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.
Narratiefupdate • Mar 17

ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside

Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.
Narratiefupdate • Mar 03

ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential

The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.
Narratiefupdate • Feb 17

ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside

Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.
Narratiefupdate • Feb 03

ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis

Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.
Narratiefupdate • Jan 20

ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing

Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.
Narratiefupdate • Jan 06

ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks

Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.
Narratiefupdate • Dec 15

ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks

Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.
Narratiefupdate • Nov 30

ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations

Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.
Narratiefupdate • Nov 16

ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm

Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.
Narratiefupdate • Nov 02

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook

Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.
Narratiefupdate • Sep 25

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.
Narratiefupdate • Aug 29

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.
Narratiefupdate • Aug 06

Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities

A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.
Analyseartikel • Aug 01

What argenx SE's (EBR:ARGX) 25% Share Price Gain Is Not Telling You

argenx SE ( EBR:ARGX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...
Analyseartikel • Jun 30

We Think argenx (EBR:ARGX) Can Stay On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
User avatar
Nieuw narratief • Apr 27

Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach

Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.

Winst- en omzetgroeiprognoses

ENXTBR:ARGX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20288,5372,9243,208N/A22
12/31/20277,2152,4163,051N/A30
12/31/20265,9301,7572,552N/A30
3/31/20264,7421,489N/AN/AN/A
12/31/20254,2361,292574685N/A
9/30/20253,6831,533N/AN/AN/A
6/30/20253,1211,280309404N/A
3/31/20252,6431,064N/AN/AN/A
12/31/20242,248833-151-83N/A
9/30/20241,909-40N/AN/AN/A
6/30/20241,660-204-325-260N/A
3/31/20241,451-328N/AN/AN/A
12/31/20231,269-295-464-420N/A
9/30/20231,029-234N/AN/AN/A
6/30/2023835-397-758-654N/A
3/31/2023639-511N/AN/AN/A
12/31/2022441-710-967-863N/A
9/30/2022286-909N/AN/AN/A
6/30/2022146-907-874-876N/A
3/31/2022381-595N/AN/AN/A
12/31/2021528-408-728-607N/A
9/30/2021510-373N/AN/AN/A
6/30/2021526-319-601-474N/A
3/31/2021206-573N/AN/AN/A
12/31/202062-608-404-398N/A
9/30/202075-535N/AN/AN/A
6/30/202070-359-263-255N/A
3/31/202073-275N/AN/AN/A
12/31/201993-181N/A152N/A
9/30/201972-109N/AN/AN/A
6/30/201968-104N/A230N/A
3/31/201970-47N/AN/AN/A
12/31/201833-76N/A-62N/A
9/30/201841-56N/AN/AN/A
6/30/201844-47N/A-57N/A
3/31/201850-46N/AN/AN/A
12/31/201749-34N/A-44N/A
9/30/201742-30N/AN/AN/A
6/30/201739-25N/A-31N/A
3/31/201723-29N/AN/AN/A
12/31/201618-22N/A11N/A
9/30/201617-20N/AN/AN/A
6/30/201614-17N/A16N/A
3/31/201612-17N/AN/AN/A
12/31/201511-17N/A-15N/A
9/30/201510-16N/AN/AN/A
6/30/20159-14N/A-10N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ARGX ( 21.6% per jaar) ligt boven de spaarquote ( 2.4% ).

Winst versus markt: De winst van ARGX ( 21.6% per jaar) zal naar verwachting sneller groeien dan de Belgian markt ( 13.8% per jaar).

Hoge groeiwinsten: De winst van ARGX zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van ARGX ( 16.9% per jaar) zal naar verwachting sneller groeien dan de markt Belgian ( 6.7% per jaar).

Hoge groei-inkomsten: De omzet van ARGX ( 16.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ARGX zal naar verwachting over 3 jaar hoog zijn ( 20.4 %)

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/21 17:53
Aandelenkoers aan het einde van de dag2026/05/21 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

argenx SE wordt gevolgd door 55 analisten. 30 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
null nullBaird
Colleen KusyBaird
Joel BeattyBaird